Tumor Necrosis Factor Blocker [EPC]

794986 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 92733
1 INJECTION SITE PAIN 57525
2 ARTHRALGIA 51742
3 PAIN 46968
4 RHEUMATOID ARTHRITIS 46333
5 OFF LABEL USE 43168
6 INJECTION SITE ERYTHEMA 41450
7 FATIGUE 34997
8 HEADACHE 28589
9 PSORIASIS 27943
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 285 0.9760
1 INJECTION SITE RECALL REACTION 481 0.9737
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 2950 0.9404
3 SWOLLEN JOINT COUNT INCREASED 578 0.9017
4 RHEUMATOID FACTOR POSITIVE 2548 0.8786
5 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1605 0.8386
6 PEMPHIGUS 5335 0.7967
7 RHEUMATIC FEVER 751 0.7914
8 C-REACTIVE PROTEIN ABNORMAL 2601 0.7762
9 HAND DEFORMITY 5485 0.7202
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]